Calcium chloride: Difference between revisions
(edited dosage forms, strengths) |
Elcatracho (talk | contribs) |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 8: | Line 8: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Hypocalcemia (emergent): 500-1000 mg IV over 5-10 minutes, repeat as needed | *[[Hypocalcemia]] (emergent): 500-1000 mg IV over 5-10 minutes, repeat as needed | ||
*Arrhythmias (emergent): 500-1000 mg IV over 5-10 minutes, repeat as needed | *Arrhythmias (emergent): 500-1000 mg IV over 5-10 minutes, repeat as needed | ||
*Hypermagnesemia: 500-1000 mg IV over 2-5 minutes, repeat if CNS depression persists | *[[Hypermagnesemia]]: 500-1000 mg IV over 2-5 minutes, repeat if CNS depression persists | ||
*Calcium channel blocker toxicity: 1-2 g IV infused over 10-20 min; repeat every 20 minutes PRN up to 5 doses | *[[Calcium channel blocker toxicity]]: 1-2 g IV infused over 10-20 min; repeat every 20 minutes PRN up to 5 doses | ||
*Beta-blocker toxicity (Refractory to glucagon/vasopressors): 1g IV bolus | *[[Beta-blocker toxicity]] (Refractory to glucagon/vasopressors): 1g IV bolus | ||
*Hyperkalemia: 1g IV | *[[Hyperkalemia]]: 1g IV | ||
*[[Cardiac Arrest]]: 1g IV (not recommended for routine use<ref>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18 Suppl 3):729-767. doi: 10.1161/CIRCULATIONAHA.110.970988. [PubMed 20956224]</ref>) | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 29: | Line 30: | ||
*Ventricular fibrillation | *Ventricular fibrillation | ||
*Do NOT administer for IM or subq | *Do NOT administer for IM or subq | ||
*Administer through central venous access except in cases of cardiac arrest | |||
**High risk of extravasation and tissue necrosis | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 52: | Line 55: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:FEN]] | ||
Latest revision as of 22:31, 29 November 2020
See critical care quick reference for drug doses by weight.
General
- Type: Mineral, Antidote
- Dosage Forms: injectable solution
- Dosage Strengths: 100 mg/mL
- Routes of Administration: IV
- Common Trade Names:
Adult Dosing
- Hypocalcemia (emergent): 500-1000 mg IV over 5-10 minutes, repeat as needed
- Arrhythmias (emergent): 500-1000 mg IV over 5-10 minutes, repeat as needed
- Hypermagnesemia: 500-1000 mg IV over 2-5 minutes, repeat if CNS depression persists
- Calcium channel blocker toxicity: 1-2 g IV infused over 10-20 min; repeat every 20 minutes PRN up to 5 doses
- Beta-blocker toxicity (Refractory to glucagon/vasopressors): 1g IV bolus
- Hyperkalemia: 1g IV
- Cardiac Arrest: 1g IV (not recommended for routine use[1])
Pediatric Dosing
See critical care quick reference for drug doses by weight.
Special Populations
- Pregnancy Rating: C
- Lactation: Infant risk cannot be ruled out
- Renal Dosing: base dosing on serum Ca if CrCl <25, may need reduced dose if on HD
- Hepatic dosing: No adjustment
Contraindications
- Allergy to class/drug
- Current use of ceftriaxone sodium injection in neonates
- Ventricular fibrillation
- Do NOT administer for IM or subq
- Administer through central venous access except in cases of cardiac arrest
- High risk of extravasation and tissue necrosis
Adverse Reactions
Serious
- Vasodilation
- Tissue necrosis (if extravasated)
Common
- Burning sensation
Pharmacology
- Half-life:
- Metabolism:
- Excretion: Renal, fecal
Mechanism of Action
- Cofoactor in many enzymatic reactions, essential for neurotransmission, muscle contraction, and many signal transduction pathways
See Also
References
- ↑ Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010;122(18 Suppl 3):729-767. doi: 10.1161/CIRCULATIONAHA.110.970988. [PubMed 20956224]